Article: CD38 Causes Age-Related NAD+ Loss and Mitochondrial Dysfunction: Preclinical Findings

PrevNext
Healthy Aging & Longevity Preclinical

CD38 Causes Age-Related NAD+ Loss and Mitochondrial Dysfunction: Preclinical Findings

Synopsis

NAD+ levels decrease with aging and are involved in age-related metabolic decline. To date, the mechanism responsible for the age-related reduction in NAD+ has not been elucidated. This study shows that the enzyme CD38, which breaks down NAD+, increases with age and causes this NAD+ loss. CD38 also leads to mitochondrial dysfunction partly by affecting SIRT3, a key mitochondrial protein. Additionally, CD38 degrades nicotinamide mononucleotide (NMN), a molecule used in NAD-boosting therapies. This identifies CD38 as a major regulator of NAD+ levels and a factor influencing NAD+ replacement treatments for aging and metabolic diseases.

Journal

Cell Metabolism

Share

Read more

Diabetes

Nicotinamide Riboside Protects Against Diabetes and Neuropathy: Preclinical Findings

SynopsisMale C57BL/6J mice fed a high-fat diet (HFD) develop prediabetes with insulin resistance and sensory neuropathy. When given low doses of streptozotocin, these mice model type 2 diabetes (T2...

Read more
Healthy Aging & Longevity

NAD+ Metabolism: Energy Production, Signaling Pathways, and Therapeutic Potential: Review

SynopsisVitamin B3's active forms, NAD+ and NADP+, are essential for energy metabolism, cell protection, and biosynthesis. Modern research shows that fluctuations in NAD+ metabolism activate signal...

Read more